ECSP066394A - Formulaciones cci-779 liofilizadas - Google Patents

Formulaciones cci-779 liofilizadas

Info

Publication number
ECSP066394A
ECSP066394A EC2006006394A ECSP066394A ECSP066394A EC SP066394 A ECSP066394 A EC SP066394A EC 2006006394 A EC2006006394 A EC 2006006394A EC SP066394 A ECSP066394 A EC SP066394A EC SP066394 A ECSP066394 A EC SP066394A
Authority
EC
Ecuador
Prior art keywords
cci
formulations
liofilized
dried
methods
Prior art date
Application number
EC2006006394A
Other languages
English (en)
Inventor
Joseph T Rubino
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34115376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066394(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP066394A publication Critical patent/ECSP066394A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen formulaciones y soluciones Liofilizadas CCI-779 útiles para la preparación de formulaciones CCI-779 secas-congeladas compuestas de CCI-779 y un solvente elegido de dimetisulfóxido, acetonitrilo, etanol, isopropanol o alcohol t-butil. También se proveen métodos para preparar las formulaciones Liofilizadas CCI-779, métodos para reconstituir los mismos y usos de los mismos.
EC2006006394A 2003-07-25 2006-02-24 Formulaciones cci-779 liofilizadas ECSP066394A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49029303P 2003-07-25 2003-07-25

Publications (1)

Publication Number Publication Date
ECSP066394A true ECSP066394A (es) 2006-08-30

Family

ID=34115376

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006394A ECSP066394A (es) 2003-07-25 2006-02-24 Formulaciones cci-779 liofilizadas

Country Status (20)

Country Link
US (1) US20050020615A1 (es)
EP (1) EP1648454A1 (es)
JP (1) JP2007500191A (es)
KR (1) KR20060052880A (es)
CN (1) CN1829514A (es)
AR (1) AR045094A1 (es)
AU (1) AU2004261163A1 (es)
BR (1) BRPI0412916A (es)
CA (1) CA2532251A1 (es)
CO (1) CO5680425A2 (es)
CR (1) CR8153A (es)
EC (1) ECSP066394A (es)
IL (1) IL172573A0 (es)
MX (1) MXPA05013865A (es)
NO (1) NO20056178L (es)
RU (1) RU2345772C2 (es)
SG (1) SG144165A1 (es)
TW (1) TW200505501A (es)
WO (1) WO2005011688A1 (es)
ZA (1) ZA200600684B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
MXPA06007829A (es) * 2004-01-08 2006-09-01 Wyeth Corp Composicion farmaceutica directamente comprimible para la administracion oral de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico.
EP1781672B1 (en) * 2004-08-27 2010-10-06 Cordis Corporation Solvent free amorphous rapamycin
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
UA109109C2 (uk) * 2009-01-15 2015-07-27 Сефалон, Інк. Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)
WO2011151704A2 (en) * 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
EP2811984B1 (en) 2012-02-06 2015-08-26 Fresenius Kabi Oncology Limited Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
CN102940630A (zh) * 2012-11-16 2013-02-27 浙江海正药业股份有限公司 含有西罗莫司酯化物的药物组合物及其制备方法
WO2014118696A2 (en) * 2013-01-29 2014-08-07 Gland Pharma Limited Pharmacuetical compositions of rapamycin esters and its derivatives
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104510708B (zh) * 2013-09-29 2018-04-24 正大天晴药业集团股份有限公司 一种米铂冻干制剂及其制备方法
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
CN105687132B (zh) * 2016-03-17 2020-06-12 鲁南贝特制药有限公司 一种坦西莫司注射用浓溶液及其制备方法
CN107773539A (zh) * 2016-08-27 2018-03-09 鲁南制药集团股份有限公司 一种注射用坦西莫司及其制备方法
CN111165656A (zh) * 2020-01-09 2020-05-19 南京大学（溧水）生态环境研究院 一种黑水虻冻干粉高效制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204775B (it) * 1986-01-31 1989-03-10 Rosella Silvestrini Kit per la determinazione dell'attivita' proliferativa nei tumori umani
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
GB9514594D0 (en) * 1995-07-17 1995-09-13 Johnson & Johnson Clin Diag Chemiluminescent analytical method
DE19936281C2 (de) * 1999-08-02 2002-04-04 Bayer Ag Verfahren zur Gefriertrocknung
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
DE60106281T2 (de) * 2000-08-11 2005-02-24 Wyeth Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
US6399625B1 (en) * 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
BR0313024A (pt) * 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
RU2326654C2 (ru) * 2002-09-17 2008-06-20 Уайт Пероральные композиции
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція

Also Published As

Publication number Publication date
RU2345772C2 (ru) 2009-02-10
AR045094A1 (es) 2005-10-12
ZA200600684B (en) 2008-07-30
JP2007500191A (ja) 2007-01-11
CR8153A (es) 2006-05-26
RU2006105645A (ru) 2006-06-27
US20050020615A1 (en) 2005-01-27
TW200505501A (en) 2005-02-16
WO2005011688A1 (en) 2005-02-10
KR20060052880A (ko) 2006-05-19
MXPA05013865A (es) 2006-02-28
IL172573A0 (en) 2006-04-10
NO20056178L (no) 2006-02-17
EP1648454A1 (en) 2006-04-26
BRPI0412916A (pt) 2006-09-26
CA2532251A1 (en) 2005-02-10
CN1829514A (zh) 2006-09-06
AU2004261163A1 (en) 2005-02-10
CO5680425A2 (es) 2006-09-29
SG144165A1 (en) 2008-07-29

Similar Documents

Publication Publication Date Title
ECSP066394A (es) Formulaciones cci-779 liofilizadas
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
BR0112693B1 (pt) (derivados) de Ácido sulfonilaminometilbenzàico substituÍdos, bem como processo para preparaÇço e uso dos mesmos.
BR9713520B1 (pt) iminas cìclicas, composição praguicida, processo para preparação e uso das referidas iminas cìclicas e da composição praguicida, bem como processo para combater pragas.
ITRM20020411A0 (it) Derivati dello spirobifluorene, loro preparazione e loro uso.
BR0113494B1 (pt) processo para a preparaÇço de uma formulaÇço sàlida herbicida, e, uso de uma formulaÇço sàlida herbicida.
BR0015254B1 (pt) compostos derivados de carbamoiloxialquil-azàlio, seu uso, bem como composiÇço farmacÊutica compreendendo os mesmos.
CO5720000A2 (es) Derivados de macrolidos con actividad antiinflamatoria, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
AR069552A1 (es) Formulaciones para el tratamiento de semillas y metodos de uso
BRPI0414000A (pt) composição farmacêutica sólida, forma de dosagem, uso da composição farmacêutica, e, método para a preparação da composição
CL2006001266A1 (es) Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas.
AR043423A1 (es) Sistema de liberacion controlada
PA8644701A1 (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ECSP034718A (es) Composiciones parasiticidas y metodos de uso
BR0107963A (pt) Dicarbamatos de dietiloctanodiol e dialofanatos de dietiloctanodiol, sua preparação e uso
CL2004000706A1 (es) Procedimiento para preparar (1h)-quinolin-2-onas-5-(alpha-haloacetil)-8-oxi-sustituidas.
DOP2002000457A (es) Tetrahidroquinolinas
NO20040614L (no) Preparater som inneholder konjugert linolalkohol.
BR9913389B1 (pt) agentes de preparaÇço, bem como precesso para sua preparaÇço.
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
BR0112419B1 (pt) chapa de pente para meio de deslocamento de pessoas.
AR005704A1 (es) Heteroariloxazolidinonas
CR6693A (es) Pirazolo (4,3-e) diazepinas sustituidas novedosas, composiciones farmaceuticas que las contienen, su uso como productos medicinales y procesos para prepararlas
UA83672C2 (en) Cci-779 lyophilized formulations